Reoperation does not provide a survival advantage in patients with recurrent Glioblastoma treated with irinotecan/bevacizumab treatment

被引：2
|
作者：
Sever, Ozlem Nuray [1 ]
Oktay, Kadir [2 ]
Guzel, Ebru [3 ]
Kaya, Vildan [5 ]
Guzel, Aslan [2 ]
Yildirim, Mustafa [4 ]
机构：
[1] Gaziantep Univ, Sch Med, Dept Internal Med & Med Oncol, Gaziantep, Turkey
[2] Med Pk Gaziantep Hosp, Dept Neurosurg, Gaziantep, Turkey
[3] Med Pk Gaziantep Hosp, Dept Radiol, Gaziantep, Turkey
[4] Med Pk Gaziantep Hosp, Dept Med Oncol, Gaziantep, Turkey
[5] Medstar Antalya Hosp, Dept Radiat Oncol, Antalya, Turkey
来源：
INDIAN JOURNAL OF CANCER | 2021年 / 58卷 / 01期
关键词：
Glioblastoma; recurrence; reoperation; survival; PROGNOSTIC-FACTORS; REPEATED SURGERY; PHASE-III; BEVACIZUMAB; TRIAL; RADIOTHERAPY; TEMOZOLOMIDE; COMBINATION; MULTIFORME; LOMUSTINE;
D O I：
10.4103/ijc.IJC_758_18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Treatment options for recurrent glioblastoma (GBM) have limited efficacy. Although reoperation is useful for both the confirmation of the diagnosis of recurring disease and the relief of the symptoms, its effect on survival is unknown. The aim of this study was to evaulate the impact of second surgery in recurrent GBM. Methods: Patients with GBM followed in our center between January 2015 and April 2018 were analyzed retrospectively based on the treatment options. Results: 25 patients diagnosed with recurrent GBM were analyzed. Ten patients (40%) were treated with chemotherapy following reoperation, and 15 patients (60%) were treated with only chemotherapy. No benefits of reoperation were observed in the univariate analysis. Conclusion: The second surgery in recurrent GBM has limited effect in clinical course.
引用
收藏
页码：91 / 95
页数：5
相关论文
共 50 条
  • [31] Prognostic factors in recurrent glioblastoma patients treated with bevacizumab
    Christina Schaub
    Julia Tichy
    Niklas Schäfer
    Kea Franz
    Frederic Mack
    Michel Mittelbronn
    Sied Kebir
    Anna-Luisa Thiepold
    Andreas Waha
    Natalie Filmann
    Mohammed Banat
    Rolf Fimmers
    Joachim P. Steinbach
    Ulrich Herrlinger
    Johannes Rieger
    Martin Glas
    Oliver Bähr
    [J]. Journal of Neuro-Oncology, 2016, 129 : 93 - 100
  • [32] Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab
    Vauleon, Elodie
    Mesbah, Habiba
    Gedouin, Daniel
    Lecouillard, Isabelle
    Louvel, Guillaume
    Hamlat, Abderrahmane
    Riffaud, Laurent
    Carsin, Beatrice
    Quillien, Veronique
    Audrain, Odile
    Lesimple, Thierry
    [J]. BULLETIN DU CANCER, 2012, 99 (02) : 121 - 126
  • [33] Does repeat usage of bevacizumab in patients with progressive recurrent ovarian cancer offer a survival advantage?
    Richardson, D. L.
    Backes, F. J.
    Seamon, L. G.
    Seamon, L. G.
    Hurt, J. D.
    Cohn, D. E.
    Fowler, J. M.
    Copeland, L. J.
    O'Malley, D. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan
    Zuniga, R. M.
    Torcuator, R.
    Doyle, T.
    Anderson, J.
    Jain, R.
    Orley, J.
    Rosenblum, M.
    Mikkelsen, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] VOLUMETRIC ASSESSMENT AND STRATIFICATION OF PATIENT SURVIVAL WITH EARLY POST-TREATMENT MRI IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB
    Huang, Raymond
    Rahman, Rifaquat
    Hamdan, Alhafidz
    Kane, Caroline
    Chen, Christina
    Norden, Andrew
    Reardon, David
    Mukundan, Srinivasan
    Wen, Patrick
    [J]. NEURO-ONCOLOGY, 2013, 15 : 197 - 197
  • [36] Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study
    Morisse, M. C.
    Etienne-Selloum, N.
    Bello-Roufai, D.
    Blonski, M.
    Taillandier, L.
    Lorgis, V.
    Noel, G.
    Ahle, G.
    Duran-Pena, A.
    Boone, M.
    Chauffert, B.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2019, 144 (02) : 419 - 426
  • [37] Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin
    Bennett, Iwan E.
    Field, Kathryn M.
    Hovens, Christopher M.
    Moffat, Bradford A.
    Rosenthal, Mark A.
    Drummond, Katharine
    Kaye, Andrew H.
    Morokoff, Andrew P.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2017, 131 (02) : 321 - 329
  • [38] Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study
    M. C. Morisse
    N. Etienne-Selloum
    D. Bello-Roufai
    M. Blonski
    L. Taillandier
    V. Lorgis
    G. Noël
    G. Ahle
    A. Durán-Peña
    M. Boone
    B. Chauffert
    [J]. Journal of Neuro-Oncology, 2019, 144 : 419 - 426
  • [39] Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin
    Iwan E. Bennett
    Kathryn M. Field
    Christopher M. Hovens
    Bradford A. Moffat
    Mark A. Rosenthal
    Katharine Drummond
    Andrew H. Kaye
    Andrew P. Morokoff
    [J]. Journal of Neuro-Oncology, 2017, 131 : 321 - 329
  • [40] Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan
    Toft, Anders
    Urup, Thomas
    Christensen, Ib Jarle
    Michaelsen, Signe Regner
    Lukram, Babloo
    Grunnet, Kirsten
    Kosteljanetz, Michael
    Larsen, Vibeke Andree
    Lassen, Ulrik
    Broholm, Helle
    Poulsen, Hans Skovgaard
    [J]. CANCER INVESTIGATION, 2018, 36 (02) : 165 - 174
12345